CryoPort (NASDAQ:CYRX) Insider Edward Zecchini Sells 33,600 Shares of Stock

CryoPort, Inc. (NASDAQ:CYRX) insider Edward Zecchini sold 33,600 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $14.47, for a total value of $486,192.00. Following the sale, the insider directly owned 109,719 shares in the company, valued at $1,587,633.93. This trade represents a 23.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

CryoPort Price Performance

CryoPort stock opened at $14.62 on Friday. CryoPort, Inc. has a one year low of $6.16 and a one year high of $16.73. The stock has a market capitalization of $736.85 million, a PE ratio of 10.83 and a beta of 1.90. The business’s fifty day moving average is $12.42 and its 200 day moving average is $10.33.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. The business had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $44.86 million. As a group, sell-side analysts expect that CryoPort, Inc. will post -0.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CYRX shares. Weiss Ratings raised CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. BTIG Research raised their price objective on CryoPort from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Craig Hallum raised their price objective on CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, June 3rd. Jefferies Financial Group set a $13.50 price objective on CryoPort in a research note on Monday. Finally, KeyCorp raised their price objective on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $15.11.

Institutional Trading of CryoPort

Several institutional investors have recently made changes to their positions in CYRX. Basepoint Wealth LLC purchased a new position in CryoPort during the 4th quarter valued at approximately $34,000. Tower Research Capital LLC TRC grew its holdings in CryoPort by 300.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after buying an additional 4,375 shares in the last quarter. AlphaQuest LLC purchased a new position in CryoPort during the 3rd quarter valued at approximately $79,000. Creative Planning purchased a new position in CryoPort during the 2nd quarter valued at approximately $96,000. Finally, Quadrature Capital Ltd purchased a new position in CryoPort during the 4th quarter valued at approximately $97,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.